V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10472697 | 10057796 | 1.84 | 87.4 | null | null | 2020-08-02 | Pentostatin | 2 | null | ABEMACICLIB + FULVESTRANT | 100903333 |
| 10472840 | 10057797 | null | null | null | null | 2018-05-13 | FCR Oral - Cycle 1 | 02 | null | BINIMETINIB + ENCORAFENIB | 101513891 |
| 10473299 | 10057800 | 0 | 90 | Palliative (P) | 2019-08-13 | 2019-10-29 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | GEMCARBO | 101188466 |
| 10473367 | 10057801 | 1.66 | 89 | Palliative (P) | 2018-01-17 | 2018-01-17 | CISPLATIN + FLUOROURACIL | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101429359 |
| 10473521 | 10057802 | 1.64 | 102 | Adjuvant (A) | 2020-04-21 | 2020-05-04 | Ofatumumab Loading | 02 | N | BELANTAMAB MAFODOTIN | 101482861 |
| 10473777 | 10057807 | 0 | 107.4 | Palliative (P) | 2020-08-21 | 2020-08-25 | CARBOPLATIN + FLUOROURACIL | 02 | N | GEFITINIB | 101465874 |
| 10473890 | 10057809 | 1.57 | 52.2 | null | 2019-09-02 | 2019-09-03 | Durvalumab | 02 | null | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 100858177 |
| 10474251 | 10057812 | 1.77 | 108 | Palliative (P) | 2021-12-02 | 2022-05-07 | Brentuximab Vedotin | N | null | GO2 TRIAL | 100075128 |
| 10474890 | 10057820 | null | 40.9 | 03 | 2022-03-31 | 2022-04-06 | ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 02 | N | CISPLATIN + PEMETREXED | 101623311 |
| 10475200 | 10057822 | 1.69 | 60 | null | 2018-07-26 | 2018-08-03 | Bendamustine + Obinutuzumab | N | null | CHLORAMBUCIL + RITUXIMAB | 100329557 |
| 10476503 | 10057832 | null | null | null | 2020-09-16 | 2021-06-02 | CVP | 02 | null | PARTNER TRIAL | 100079048 |
| 10476536 | 10057833 | 1.68 | 52.4 | null | 2018-04-13 | 2018-04-14 | GEMCITABINE + NAB PACLITAXEL | 02 | null | CISPLATIN + FLUOROURACIL + RT | 101716424 |
| 10476546 | 10057834 | 1.65 | null | null | 2017-10-17 | 2017-10-17 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101634362 |
| 10476616 | 10057835 | 1.68 | 70 | Disease modification (D) | 2021-08-16 | 2021-12-13 | null | 2 | N | CLADRIBINE | 100313512 |
| 10476699 | 10057836 | 1.72 | 89 | null | null | 2020-09-19 | BCG Intravesical | N | null | DOXORUBICIN + OLARATUMAB | 101630583 |
| 10476731 | 10057837 | 1.74 | 89 | Palliative (P) | 2018-04-10 | 2018-05-16 | Cetuximab + Radiotherapy Maint | 2 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + OBINUTUZUMAB + VINCRISTINE | 101747177 |
| 10476809 | 10057839 | 1.55 | 56 | Disease modification (D) | 2019-09-28 | 2019-12-30 | BOSUTINIB | 2 | N | THALIDOMIDE | 100367528 |
| 10476822 | 10057840 | null | null | null | 2018-09-26 | 2018-09-27 | GEMCITABINE + NAB PACLITAXEL | 02 | null | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101273115 |
| 10476843 | 10057841 | 0 | 63.6 | Curative (C) | 2020-12-07 | 2020-12-28 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | STAMPEDE TRIAL | 100134368 |
| 10477017 | 10057844 | 1.6 | 69.9 | null | 2021-06-28 | 2021-07-16 | null | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101585803 |
| 10477134 | 10057845 | 1.65 | 71 | null | null | 2016-05-16 | BRIGATINIB | 02 | null | AML18 TRIAL | 100552561 |
| 10477144 | 10057846 | 1.68 | 83 | null | 2017-10-03 | 2018-07-20 | Bevacizumab | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 101169350 |
| 10477187 | 10057848 | 1.69 | null | Palliative (P) | 2017-10-08 | 2017-10-08 | Carboplatin + Cetux + FU (Cycle 1) | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101650732 |
| 10477213 | 10057850 | 1.81 | 76.2 | Palliative (P) | null | 2020-01-14 | Sunitinib | 02 | N | CAPECITABINE + CISPLATIN | 101390086 |
| 10477542 | 10057852 | 1.56 | 72.5 | null | 2018-02-04 | 2018-04-27 | EOX | 02 | null | BELANTAMAB MAFODOTIN | 100288084 |
| 10477608 | 10057854 | 1.88 | 63.3 | Palliative (P) | 2018-02-17 | 2019-06-29 | Matrix Lung Trial | 02 | N | ERLOTINIB | 100258500 |
| 10477696 | 10057856 | 1.82 | 0 | Curative (C) | 2021-04-26 | 2021-05-04 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101247612 |
| 10477850 | 10057858 | 1.57 | 58.6 | null | 2020-01-06 | 2020-01-06 | Docetaxel + nintedanib | 02 | null | BEXAROTENE | 100777684 |
| 10478176 | 10057863 | 1.7 | 69.3 | Palliative (P) | 2021-01-19 | 2021-12-21 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | CARBOPLATIN + DOCETAXEL | 100836889 |
| 10478682 | 10057865 | null | null | null | 2020-01-19 | 2020-02-20 | FEC 60 or 75 | 99 | null | ABEMACICLIB + FULVESTRANT | 101181935 |
| 10478706 | 10057866 | 1.75 | 0 | null | 2019-07-02 | 2019-07-15 | null | 2 | null | FLUOROURACIL + MITOMYCIN | 100376229 |
| 10478975 | 10057870 | 1.69 | 101.6 | Palliative (P) | 2022-03-22 | 2022-04-19 | Bexarotene | 02 | null | IXAZOMIB | 100349456 |
| 10479050 | 10057871 | 1.73 | 76 | null | 2020-03-01 | 2020-03-22 | Irinotecan | 02 | null | THALIDOMIDE | 101216618 |
| 10479451 | 10057874 | 1.72 | 64 | null | 2015-10-12 | 2018-10-29 | THALIDOMIDE | 02 | null | VISMODEGIB | 100627546 |
| 10479694 | 10057876 | 1.62 | 98 | null | 2019-02-24 | 2019-03-07 | Mitomycin Intravesical | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101251254 |
| 10480458 | 10057883 | 1.59 | 103.4 | null | 2018-04-24 | 2018-06-01 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101221005 |
| 10480650 | 10057885 | 1.53 | 58.5 | null | 2020-04-07 | 2020-05-29 | Trial Unspecified | 02 | null | RUCAPARIB | 101161113 |
| 10480710 | 10057886 | 1.52 | 82.6 | null | 2016-09-05 | 2016-10-18 | PEG INTERFERON | N | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100014245 |
| 10480742 | 10057887 | 1.69 | 63.4 | null | 2019-05-05 | 2019-05-21 | DA-EPOCH-R | 02 | null | MITOMYCIN | 101861899 |
| 10481450 | 10057893 | 1.76 | 70.2 | Palliative (P) | 2021-12-09 | 2022-01-03 | Cyclophos + Dex + Lenalidomide | 02 | N | LIPOSOMAL DOXORUBICIN | 100563695 |
| 10000298 | 10057897 | 1.74 | 77.2 | null | 2019-12-23 | 2020-01-06 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | Y | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101244197 |
| 10001902 | 10057898 | null | null | Palliative (P) | 2019-05-28 | 2020-05-27 | ISATUXIMAB + POMALIDOMIDE | 2 | N | PAZOPANIB | 101754306 |
| 10023603 | 10057902 | 1.83 | 88.3 | null | null | 2020-07-26 | FEC | 02 | null | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100822150 |
| 10028896 | 10057905 | 1.83 | 88.3 | Palliative (P) | 2018-04-11 | 2018-06-12 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | null | N | FLUOROURACIL + MITOMYCIN | 101710164 |
| 10040757 | 10057906 | null | null | null | 2015-06-19 | 2015-06-29 | Cyclophos + Dex + Lenalidomide | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101688093 |
| 10048165 | 10057908 | 1.81 | 102 | Palliative (P) | 2019-12-12 | 2019-12-17 | null | 02 | N | CAPECITABINE + CARBOPLATIN | 101006788 |
| 10057843 | 10057909 | 1.8 | 106.5 | Palliative (P) | 2020-02-15 | 2020-02-15 | null | 01 | Y | FLAIR TRIAL | 101687648 |
| 10068099 | 10057911 | 1.8 | 77.7 | null | 2018-05-01 | 2019-02-15 | Doxorubicin chemoembolisation | 02 | null | CAPECITABINE + CISPLATIN | 100901461 |
| 10071164 | 10057912 | null | null | Palliative (P) | 2017-04-13 | 2017-04-18 | VISMODEGIB | 02 | N | FLUOROURACIL + MITOMYCIN | 101515610 |
| 10071902 | 10057913 | 1.85 | 91.4 | null | 2015-11-16 | 2020-03-24 | null | 02 | null | NAB-PACLITAXEL | 100952302 |